CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma

Clinical Investigation of Chimeric Costimulatory Converting Receptor(CCCR)-Modified NK92 Cells in Previously Treated Advanced Non-small Cell Lung Carcinoma

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03656705

Enrollment

Registered

2018-09-04

Start date

2018-09-29

Completion date

2020-12-31

Last updated

2023-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer

Brief summary

The purpose of this clinical investigation is to evaluate the safety and effects of CCCR-modified NK92(CCCR-NK92)infusions in previously treated advanced non-small cell lung carcinoma(NSCLC).

Interventions

BIOLOGICALCCCR-NK92 cells

CCCR-NK92 cells will be administered intravenously over 1h. The starting dose of CCCR-NK92 cells will be 1×10e7-1×10e8,twice a week. The first evaluation of the efficacy after 3 weeks of treatment.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* 1.Male and female subjects with non-small cell lung carcinoma in patients with no available curative treatment options who have limited prognosis(≧3 months)with currently available therapies will be enrolled. * 2.The last cytotoxic drug, radiotherapy or surgery≧4 weeks. * 3.HB≧90g/L, ANC≧1.5×10e9/L, PLT≧80×10e9/L, TBIL≦1.5×upper limit of nomal, ALT/AST≦2.5×upper limit of nomal, ALT/AST≦5×upper limit of nomal if have liver metastasis, Cr≦1.5×upper limit of nomal or CCr≧60ml/min.

Exclusion criteria

* 1.Pregnancy or breastfeeding. * 2.Known HIV, HBV or HCV infection. * 3.Active antoimmune disease. * 4.History of severe immediate hypersensitivity to any of the biological products including penicillin. * 5.Severe psychiatric disorder which might interfere with the study treatment or examination. * 6.Chronic heart failure NYHA≧III. * 7.Simultaneous participation in another clinical trial within 4 weeks.

Design outcomes

Primary

Measure	Time frame	Description
Number of participants with adverse events evaluated with CTCAE,version 4.0	3 months	Safety evaluation
Objective Response Rate	up to one year	Non-small cell lung carcinoma to CCCR-NK92 cell infusions

Secondary

Measure	Time frame
Progression-free Survival	up to one year
Overall Survival	up to one year
Disease Control Rate	up to one year

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026